Involvement of Urokinase-Type Plasminogen Activator System in Cancer: An Overview.
- Published in:
- Medicinal Research Reviews, 2014, v. 34, n. 5, p. 918, doi. 10.1002/med.21308
- By:
- Publication type:
- Article
Works matching AU Pourgholami, Mohammad H.
Results: 14
1
2
Potent inhibition of tumoral hypoxia-inducible factor 1alpha by albendazole.
- Published in:
- 2010
- By:
- Publication type:
- journal article
3
Potent inhibition of tumoral hypoxia-induciblefactor 1α by albendazole.
- Published in:
- BMC Cancer, 2010, v. 10, p. 143, doi. 10.1186/1471-2407-10-143
- By:
- Publication type:
- Article
4
Minocycline Suppresses Interleukine-6, Its Receptor System and Signaling Pathways and Impairs Migration, Invasion and Adhesion Capacity of Ovarian Cancer Cells: In Vitro and In Vivo Studies.
- Published in:
- PLoS ONE, 2013, v. 8, n. 4, p. 1, doi. 10.1371/journal.pone.0060817
- By:
- Publication type:
- Article
5
Anti-MUC1 Monoclonal Antibody (C595) and Docetaxel Markedly Reduce Tumor Burden and Ascites, and Prolong Survival in an in vivo Ovarian Cancer Model.
- Published in:
- PLoS ONE, 2011, v. 6, n. 9, p. 1, doi. 10.1371/journal.pone.0024405
- By:
- Publication type:
- Article
6
Pilot Study of Albendazole in Patients with Advanced Malignancy.
- Published in:
- Oncology, 2001, v. 61, n. 1, p. 42, doi. 10.1159/000055351
- By:
- Publication type:
- Article
7
1,25-Dihydroxyvitamin D<sub>3</sub> induced cell cycle arrest in the human primary liver cancer cell line HepG2
- Published in:
- Hepatology Research, 2003, v. 26, n. 1, p. 34, doi. 10.1016/S1386-6346(02)00328-5
- By:
- Publication type:
- Article
8
Phase I clinical trial to determine maximum tolerated dose of oral albendazole in patients with advanced cancer.
- Published in:
- 2010
- By:
- Publication type:
- Report
9
Antitumor activity of albendazole against the human colorectal cancer cell line HT-29: in vitro and in a xenograft model of peritoneal carcinomatosis.
- Published in:
- Cancer Chemotherapy & Pharmacology, 2005, v. 55, n. 5, p. 425, doi. 10.1007/s00280-004-0927-6
- By:
- Publication type:
- Article
10
MUC1 has prognostic significance in malignant peritoneal mesothelioma.
- Published in:
- International Journal of Biological Markers, 2013, v. 28, n. 3, p. 303, doi. 10.5301/JBM.5000038
- By:
- Publication type:
- Article
11
Albumin nanoparticles increase the anticancer efficacy of albendazole in ovarian cancer xenograft model.
- Published in:
- Journal of Nanobiotechnology, 2015, v. 13, n. 1, p. 1, doi. 10.1186/s12951-015-0082-8
- By:
- Publication type:
- Article
12
Expression patterns of ERα66 and its novel variant isoform ERα36 in lactotroph pituitary adenomas and associations with clinicopathological characteristics.
- Published in:
- Pituitary, 2020, v. 23, n. 3, p. 232, doi. 10.1007/s11102-020-01029-z
- By:
- Publication type:
- Article
13
An Optimized RGD-Decorated Micellar Drug Delivery System for Albendazole for the Treatment of Ovarian Cancer: From RAFT Polymer Synthesis to Cellular Uptake.
- Published in:
- Macromolecular Bioscience, 2011, v. 11, n. 2, p. 219, doi. 10.1002/mabi.201000293
- By:
- Publication type:
- Article
14
Peritoneal mesothelioma in a woman who has survived for seven years: a case report.
- Published in:
- 2011
- By:
- Publication type:
- journal article